Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95364 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL3036894 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831413 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL866108 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831588 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL866938 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL867290 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL22524 | 0.97 | — | — | |
| SCHEMBL29156058 | 0.94 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL25313563 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1015 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233786-B | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-11-26 | — | — | CN | claimed |
| CN-111233786-A | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-06-05 | — | — | CN | claimed |
| EP-3597670-B1 | WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE | ADEKA CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240176236-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-118103209-A | Composition for forming release layer, laminate, and method for producing laminate | 日产化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-114616254-B | Acylphosphine composition, polymerization initiator, polymerizable composition, cured product, and method for producing same | 株式会社ADEKA | 2024-03-15 | — | — | CN | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-113166554-B | xanthene compounds | 株式会社艾迪科 | 2023-12-12 | — | — | CN | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-0212647-A2 | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins | SYNTEX (U.S.A.) INC. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4551459-A | Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides | SYNTEX (U.S.A.) INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0153152-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4490371-A | ANTICOAGULANTS, PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0116948-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-(2,1-b)quinazolinyl)-oxyalkyl-amides | SYNTEX (U.S.A.) INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4425362-A | CARDIOVASCULAR DISORDERS, ADRENERGIC BLOCKING AGENTS | SANDOZ LTD. (CH) | 1984-01-10 | — | — | US | disclosed |
| US-4389345-A | 3-Oxoestra-17-acetonitrile and unsaturated analogs | G.D. SEARLE & CO. (US) | 1983-06-21 | — | — | US | disclosed |
| EP-0077040-A1 | 3-Oxaestra-17-acetonitrile and unsaturated analogs, a process for their preparation and pharmaceutical compositions containing said compounds | G.D. Searle & Co. (US) | 1983-04-20 | — | — | EP | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | CYP1A2 23/4885SIGMAR1 1736/4885EPHX1 4209/4885 |
| US-20240176236-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | PAG1, KAT5, SLC6A5 | CYP1A2 3930/4885SIGMAR1 287/4885EPHX1 2461/4885 |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | F12, F10, PCNA | CYP1A2 356/4885SIGMAR1 2719/4885EPHX1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.